IBI188 + cisplatin + carboplatin + bevacizumab + pemetrexed

This is a combination therapy consisting of five agents: - **IBI188**: a fully human monoclonal antibody targeting CD47, acts by blocking the CD47-SIRPα signaling pathway, thereby promoting macrophage-mediated tumor cell phagocytosis and enhancing anti-tumor immunity[1][3][5][7]. - **Cisplatin**: a platinum-based chemotherapeutic agent that forms DNA cross-links and induces apoptosis in rapidly dividing cells. - **Carboplatin**: another platinum-based chemotherapeutic with similar DNA cross-linking action, but a different toxicity profile from cisplatin. - **Bevacizumab**: a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis essential for tumor growth and metastasis[2][4]. - **Pemetrexed**: an antimetabolite that inhibits folate-dependent enzymes required for DNA and RNA synthesis, leading to growth inhibition of rapidly proliferating tumor cells[4][6]. This combination leverages immunomodulation (via CD47 blockade), platinum-induced DNA damage, anti-angiogenic effects, and antimetabolite cytotoxicity, and is investigated primarily in advanced solid tumors such as non-small cell lung cancer and other malignancies in clinical trials[1][4][5].